Tiffany Avery MD MPH
Chief Medical Officer, NantHealth
- LBBC Medical Advisory Board member since 2020
- Chief Medical Officer, NantHealth
- Cohost of 3 Black Docs podcast
Connect with Dr. Avery
Dr. Tiffany Avery is board-certified Medical Oncologist with a special interest in breast cancer and differences in cancer survival. After completing fellowship training at MD Anderson Cancer Center in Houston, Dr. Avery focused on clinical research and the care of breast cancer patients.
She conducted clinical trials for breast cancer patients, secured grant funding to study survival differences among breast cancer patients and presented lectures to medical colleagues and trainees on these topics. In the community, Dr. Avery has been an invited speaker to discuss topics that include cancer prevention, treatments, clinical trials, and survival disparities in cancer. Dr. Avery is also the founder of CancerCall, a company dedicated to patient education and empowerment as a tool to impact cancer disparities.
Dr. Avery is a proud New Orleans native currently living in North Carolina with her husband and two sons. She enjoys running, gardening, and yoga. Dr. Avery also cohosts 3 Black Docs, a weekly podcast dedicated to educating the community about health and health disparities in an approachable and entertaining way.
In treating breast cancer patients, I think it’s really important for there to be a partnership between the oncologist and their patient, so that the patient feels they really understand why I’m recommending the things I am, and that they feel empowered that they have a voice and a say in how their cancer treatment goes.
Experience & Accolades
Medical Oncology, Hematology
- Louisiana State University School of Medicine New Orleans
- Doctor of Medicine – 2003
- Tulane University
- Bachelor of Science, Psychology – 1997
- Master of Public Health – 1999
In the Media
- Wake Forest Baptist Health - Tiffany Avery, MD – Hematology and Oncology
- 5 Things We Must Do To Improve the US Healthcare System - Dr. Tiffany Avery of NantHealth
Professional Memberships and Board Positions
- Monitoring Neoadjuvant Chemotherapy for Breast Cancer by Using Three-dimensional Subharmonic Aided Pressure Estimation and Imaging with US Contrast Agents: Preliminary Experience.Nam, K.,Eisenbrey, J. R.,Stanczak, M.,Sridharan, A.,Berger, A. C.,Avery, T.,Palazzo, J. P.,Forsberg, F.
- Erythropoiesis stimulating agents and clinical outcomes of invasive breast cancer patients receiving cytotoxic chemotherapy. Lai, Y.,Palazzo, J. P.,Cristofanilli, M.,Hyslop, T.,Civan, J.,Avery, T.,Myers, R. E.,Li, B.,Ye, Z.,Xing, J.,Yang, H.
Targeted therapy for hormone-receptor positive breast cancer
Targeted therapies are treatments that target specific proteins or markers on or within cancer cells that help cancer cells grow. There are many different kinds of targeted therapy. Hormonal therapy is a type of targeted therapy because it targets hormones that are active in cancer growth.
Neratinib (Nerlynx) is a targeted therapy for people with HER2-positive breast cancer. It is the first medicine for people with HER2-positive breast cancer approved as extended therapy, meaning that for early-stage disease, it is given after primary treatment ends to lower the risk of cancer coming back.
Pertuzumab (Perjeta) is a targeted therapy used to treat early-stage and metastatic HER2-positive breast cancer. Pertuzumab is a monoclonal antibody, a type of medicine made in a lab that targets a specific protein, HER2, produced on the outside of a cell. It falls in a class of medicines called targeted therapies.
The medicine trastuzumab (Herceptin and biosimilars) is the most common medicine used to treat HER2-positive breast cancer. It is a monoclonal antibody, a medicine made in a lab that attacks a specific protein produced on the outside of a cell. It falls in a class of medicines called targeted therapies.
Tucatinib (Tukysa) is a tyrosine kinase inhibitor used to treat metastatic, HER2-postive breast cancer. It is given with another targeted therapy, trastuzumab (Herceptin), and the chemotherapy pill capecitabine (Xeloda) to treat cancers that have grown after previous HER2-targeted treatments.
What you need to know about breast cancer, with “3 Black Docs”
Karen Winkfield, MD, PhD; Tiffany Avery, MD, MPH; and Zanetta Lamar, MD, are the hosts of “3 Black Docs,” a weekly podcast where they explore health, community, and life over cocktails. In this interview, they discuss the basics of breast cancer for Black women. Available as video, audio, and in a transcript.